GHRH and neoplasm: Synthetic GHRH-Ant were then produced in order to develop a class of anti-cancer agents, demonstrating inhibition of human tumor growth in vitro and in vivo against renal [15], bone [16], breast [17, 18], pancreatic [19], prostatic [20, 21], colorectal [22], and lung cancers [23].